ABSTRACT
Objectives To perform an international comparison of the trajectory of laboratory values among hospitalized patients with COVID-19 who develop severe disease and identify optimal timing of laboratory value collection to predict severity across hospitals and regions.
Design Retrospective cohort study.
Setting The Consortium for Clinical Characterization of COVID-19 by EHR (4CE), an international multi-site data-sharing collaborative of 342 hospitals in the US and in Europe.
Participants Patients hospitalized with COVID-19, admitted before or after PCR-confirmed result for SARS-CoV-2.
Primary and secondary outcome measures Patients were categorized as “ever-severe” or “never-severe” using the validated 4CE severity criteria. Eighteen laboratory tests associated with poor COVID-19-related outcomes were evaluated for predictive accuracy by area under the curve (AUC), compared between the severity categories. Subgroup analysis was performed to validate a subset of laboratory values as predictive of severity against a published algorithm. A subset of laboratory values (CRP, albumin, LDH, neutrophil count, D-dimer, and procalcitonin) was compared between North American and European sites for severity prediction.
Results Of 36,447 patients with COVID-19, 19,953 (43.7%) were categorized as ever-severe. Most patients (78.7%) were 50 years of age or older and male (60.5%). Longitudinal trajectories of CRP, albumin, LDH, neutrophil count, D-dimer, and procalcitonin showed association with disease severity. Significant differences of laboratory values at admission were found between the two groups. With the exception of D-dimer, predictive discrimination of laboratory values did not improve after admission. Sub-group analysis using age, D-dimer, CRP, and lymphocyte count as predictive of severity at admission showed similar discrimination to a published algorithm (AUC=0.88 and 0.91, respectively). Both models deteriorated in predictive accuracy as the disease progressed. On average, no difference in severity prediction was found between North American and European sites.
Conclusions Laboratory test values at admission can be used to predict severity in patients with COVID-19. Prediction models show consistency across international sites highlighting the potential generalizability of these models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GW reports funding from NCATS UL1TR002541, NCATS UL1TR000005, and NLM R01LM013345. SM and JK report funding from NCATS 5UL1TR001857-05 and NHGRI 5R01HG009174-04. ZX reports funding from NINDS R01NS098023. GO reports funding from NIH grants NIEHS P30ES017885 and NCI U24CA210967. SV reports funding from NLM R01LM012095 and NCATS UL1TR001857. AS reports funding from NHLBI K23HL148394 and L40HL148910, and NCATS UL1TR001420. BA reports funding from NHLBI U24 HL148865. DB and RF report funding from NCATS UL1TR001881. TG and TG report funding from 01ZZ1801E German Federal Ministry of Education and Research. DH reports funding from NCATS UL1TR002240. MK reports funding from NHGRI 5T32HG002295-18. DK reports funding from MIRACUM Consortium grant 01ZZ1801A. YL reports funding from NLM R01LM01333. JM reports funding from NCATS UL1TR001878. DM reports funding from NCATS UL1-TR001878 Institutional Clinical and Translational Science Award (University of Pennsylvania). LP reports funding from NCATS CTSA Award #UL1TR002366. SD, KL, and MM report funding from Veterans Affairs VA HSR RES 13-457. MPJ reports funding from the Carlos III Health Institute, grant PI18/00981.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB Approval was obtained at Assistance Publique - Hopitaux de Paris, Erlangen University Hospital, University Medicine Mannheim, Policlinico di Milano, ASST Papa Giovanni XXIII Bergamo, University of Kansas Medical Center, UT Southwestern Medical Center, Northwestern University, University of Pittsburgh / UPMC, University of Alabama at Birmingham, Hospital Universitario 12 de Octubre, Wake Forest School of Medicine & Brenner Children's Hospital, University Magna Graecia of Catanzaro & Mater Domini University Hospital, VA New England Health Care System, VA Healthcare New York/New Jersey, VISN4 network, VA Capitol Healthcare Network, VA Mid-Atlantic Health Care Network, VA Southeast Network, VA Sunshine Healthcare Network, VA MidSouth Healthcare Network, VA Healthcare System VISN10, VA Great Lakes Healthcare System, VA Heartland Network, South Central VA Healthcare Network, VA Heart of Texas Healthcare System, VA Rocky Mountain Network, VA Northwest Health Network, VA Sierra Pacific Network, VA Desert Pacific Healthcare Network, and VA Midwest Healthcare Network. An exempt determination was made by Institutional Review Boards at Bordeaux University Hospital, Medical Center, University of Freiburg, Beth Israel Deaconess Medical Center, Mass General Brigham (Partners Healthcare), University of Pennsylvania, University of California LA, and University of Michigan. An IRB waiver was obtained at Instituti Clinici Scientifici Maugeri Hospitals, National University Hospital, Medical University of South Carolina, National University Health System, and St. Luke's University Health Network.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Only aggregate data was shared by sites for this study. All aggregate data in a de-identified fashion can be found and downloaded at www.covidclinical.net.
